Current Initiatives

April 2022

Help us advocate for expanded access to nintedanib for all pulmonary fibrosis patients

As of now, nintedanib (Ofev) is included in the drug formulary list and reimbursement is provided to people with any chronic fibrosing ILD (interstitial lung disease) in the following provinces/territories:

– Alberta (April 1, 2022)
– Quebec (April 13, 2022)
– Newfoundland & Labrador (April 22, 2022)
– Northwest Territories (April 22, 2022)
– Ontario (April 29, 2022)
– New Brunswick (April 29, 2022)
– Nova Scotia (May 13, 2022)
– Manitoba (June 1, 2022)
– Saskatchewan (June 1, 2022)
– British Columbia (June 7, 2022)
– Prince Edward Island (June 10, 2022)

It is also worth noting that the First Nations and Inuit (NIHB) Non-Insured Health Benefits have also come on board!

For all other provinces/territories, fill out the form below to urge your provincial/territorial government to include nintedanib (Ofev) on their drug formulary list and provide reimbursement to all people with any chronic fibrosing ILD. Act now.

If you’re an Alberta, Quebec, Newfoundland & Labrador, Northwest Territories, Ontario, New Brunswick, Nova Scotia, Manitoba, Saskatchewan, British Columbia or Prince Edward Island resident, stay tuned, as we will make it possible for you to send a thank you letter to your government by filling out the form in the future.

On May 25, 2020, Health Canada announced that nintedanib could now be used to treat progressive fibrosing interstitial lung diseases (PF-ILD). Before then, nintedanib was only approved to treat idiopathic pulmonary fibrosis (IPF) patients.

CADTH and INESSS recommended that nintedanib be reimbursed for the treatment of other PF-ILDs last year and earlier this year, the pan-Canadian Pharmaceutical Alliance (pCPA) completed negotiations for the pricing of nintedanib, (Ofev) for treating all PF-ILD.

Despite this news, nintedanib is still not listed (except in Alberta, Quebec, Newfoundland & Labrador, the Northwest Territories, Ontario, New Brunswick, Nova Scotia, Manitoba, Saskatchewan, British Columbia and Prince Edward Island) on all provincial/territorial drug formularies, nor is it reimbursed for people with PF-ILD, other than IPF.

Now, we need our government representatives to accept the CADTH recommendation and provide full coverage for this medication for all ILD patients who will benefit from its use. Those suffering with the breathlessness and bleak prognosis of PF-ILD cannot wait.